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ABSTRACT 
Background: Rapid reviews provide an efficient alternative to standard systematic reviews in 
response to a high priority or urgent need. Although rapid reviews of interventions have been 
extensively evaluated, little is known about the characteristics of rapid reviews of diagnostic 
evidence.  
Study design and setting:  We performed a scoping review for rapid reviews of medical tests 
published from 2013 to 2018. We extracted information on review characteristics and methods used 
to assess the evidence.  
Results: We identified 191 rapid reviews. All reviews were developed within a short time (less than 
12 months) and were relatively concise (less than 10 pages). The reviews involved multiple index 
tests (44%), multiple outcomes (88%), and several test applications (29%). Well-known 
methodological tailoring strategies were infrequently used. Although reporting of several key 
features was limited, we found that, in general, rapid reviews have similar characteristics to broader 
knowledge syntheses.  
Conclusion: Our scoping review is the first to describe the characteristics and methods of rapid 
reviews of diagnostic evidence. Future research should identify the most appropriate methods for 
performing rapid reviews of medical tests. Standards for reporting of rapid reviews are needed.  
 
Keywords 
Medical tests, rapid reviews, health-technology assessment, knowledge synthesis 
 
Running title: A scoping review for rapid reviews of medical tests published from 2013 to 2018 
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What is new?  
Key findings  
• Our scoping review identified 191 rapid reviews of medical tests from 15 countries published 
between 2013 and 2018. 
• Most rapid reviews were broad in scope and assessed multiple index tests, outcomes, and test 
applications. In general, well-known methodological tailoring strategies, such as setting limits for 
literature searching by date or language or searching a single database, were rarely used.  
• Information about parallelisation of tasks and the use of automated approaches was infrequently 
reported. 
 
 What this adds to what was known?  
• Rapid reviews of medical tests have many of the same characteristics and use similar methods as 
those of standard systematic reviews. However, we found that several critical items for rapid 
reviews were infrequently reported. 
 
What is the implication and what should change now? 
• Standards for reporting of rapid reviews are needed. Those standards would cover the essential 
items that should be included in every rapid review. 
• Further research should inform the most appropriate methods for performing rapid reviews of 
medical tests. 
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INTRODUCTION 
The accurate and unbiased assessment of the value of healthcare-related tests and diagnostic 
strategies (i.e. medical tests) in existing clinical pathways has emerged as a critical issue for 
healthcare decision-making, mostly driven by the pace of technological advancement in recent 
years (1, 2). Standard systematic reviews (SR) have been the leading approach for the formal 
evaluation of the quality, extent and effects of healthcare evidence (3-5), and evidence regarding 
the use of medical tests is no exception (6-8). The process of performing and maintaining systematic 
reviews on diagnostic tests has been developed and standardised in past years, including methods 
for searching for studies, study selection, quality assessment, and data synthesis (2, 9-11). 
 
The conduction of SR involves considerable time and resources which might not be available in 
sensitive clinical scenarios, such as emergencies or disease outbreaks (12). Recently, Beese et al. 
estimated that the probability of completing an SR of diagnostic test accuracy in 24 months was less 
than 10%, increasing to 33% if reviewers invested twice the time in its development (13). In such 
situations, rapid reviews (RR) have emerged as a pragmatic and efficient alternative to speed-up the 
evidence synthesis process. In comparison to SR, RR take less time to perform by increasing the 
intensity of work using methodological tailoring (review shortcuts) and by automating review tasks 
to streamline the process (6, 14-16). Two examples of RR developed within time constraints are the 
RR performed by Ismail et al on the challenges to disease surveillance in the context of the crisis in 
Syria, and the RR developed by Banbury et al on the impact of e-health for rural residents developed 
in Australia, both developed in less than seven weeks (17, 18). 
 
At present, there is no commonly accepted definition for RR (14, 19, 20). In their analysis of rapid 
assessment products, Hartling et al. concluded that a RR is “true” when evidence synthesis is carried 
out to provide an answer about the direction of the evidence collected, and, if possible, the strength 
of these findings, while meeting important time constraints (14, 19, 21). Methods to enhance the 
timeliness of these knowledge syntheses can be classified into four categories: a) those limiting the 
range of populations, interventions and outcomes assessed (narrow the scope); b) those increasing 
the intensity of the work on review processes (parallelisation of tasks); c) those focusing on 
methodological tailoring of SR steps according to the needs of decision-makers (review shortcuts) 
and; d) those using new technologies to fast-track SR steps (automated steps) (1, 12). 
 
The assessment of diagnostic evidence to inform policy decisions presents some particular 
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challenges in comparison with intervention evidence. Reviews for diagnostic test accuracy should 
specify the purpose (application) and role of the test and its placement in the clinical pathway. In 
comparison with intervention reviews, the statistical aspects of diagnostic accuracy reviews are 
more challenging, often requiring hierarchical models for meta-analysis. To our knowledge, a 
comprehensive review of RRs for medical tests has not yet been performed. Hence, as a first step, 
this article will map the methods currently used to produce RR of diagnostic research.  
 
In this scoping review, we aimed to identify recently published RR of medical tests and to describe 
their characteristics and methods. This exploration may also help to identify shortcomings of current 
RR and needs for future research. 
 
METHODS 
PROTOCOL AND REGISTRATION 
The protocol for this review was published on the Open Science Framework platform for public 
consultation (22). Authors of the review drafted, revised and approved this document for 
publication.  
ELIGIBILITY CRITERIA 
We included reports fulfilling all of the following criteria: 
• Reports defined by the review authors as a “rapid review” of the evidence. In the case of 
reports defined only as a rapid product or a rapid assessment, we applied the definitions of 
Hartling et al. and selected as eliglble those classified as “True Rapid Review” (14, 21). 
• Reports that evaluated a healthcare-related test or diagnostic test strategy for any purpose 
and in any setting. 
• Reports published from 2013 to 2018 to reflect methods in current use by RR developers. 
We searched for RR without language restriction. We excluded states of the art, evidence 
inventories, or rapid responses (following the definition of Hartling et al. (14, 21)), original versions of 
updated RR, and manuscripts unavailable as full-text articles when requested by our review team.  
 
INFORMATION SOURCES 
We searched for eligible RR as follows: 
Searching institutional websites and repositories: We conducted a manual search of public 
repositories  belonging to members of the International Network of Agencies for Health Technology 
7 
 
Assessment (INAHTA), World Health Organization (WHO) Collaborating Centres on Health 
Technology Assessment (HTA) and Health Technology Assessment International Network (HTAi; non-
profit members). In addition, we screened the Regional Database of Health Technology Assessment 
reports in Americas (REDETSA/BRISA) and the EUnetHTA’s Assessment Rapid Relative Effectiveness 
Assessments (REA) repositories and archives. This manual search was conducted in September 2018. 
Searching electronic databases: We searched MEDLINE-OVID 1946 to present, EMBASE (Elsevier), the 
Cochrane Library and LILACS in September 2018. An experienced librarian developed the search 
strategies for each indexed database, including a combination of controlled vocabulary and other 
related search terms and filters in order to retrieve RR (Appendix 1). 
SELECTION OF SOURCES OF EVIDENCE 
One review author examined institutional repositories for RR, and those that were deemed 
potentially eligible were downloaded for further assessment. When these documents were 
unavailable due to restrictions, we requested permission to access them from their respective 
institutions. Four review authors confirmed the final eligibility for each RR. In addition, for the 
electronic searches, two review authors first screened records based on title and abstract and then 
confirmed eligibility after reviewing full-text articles. We resolved all disagreements by discussion. 
DATA CHARTING PROCESS 
One review author extracted data in a standardised format for each RR on the following features: 
general characteristics of the review, the research question, index test(s), target condition(s), 
application(s) of the test, and pre-planned outcome(s). In addition, we extracted information on key 
RR strategies reported in the literature: narrowing the scope, parallelisation of tasks, review 
shortcuts, and automated approaches (16, 20, 23). Four different review authors confirmed data 
extraction for 10% of the included reviews. We resolved all disagreements by discussion. We used 
operational definitions of variables to standardise data extraction (Appendix 2). Since no RR reported 
the length of time to develop the review, we estimated the duration using either a) the date of the 
last search strategy and the publication date for reviews published on public repositories; or b) the 
date of the last search strategy and the submission date for reviews published in peer-reviewed 
journals (24). 
SYNTHESIS OF RESULTS 
We analysed the information descriptively using STATA 15.0.  
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RESULTS 
SELECTION OF SOURCES OF EVIDENCE 
Institutional websites and repositories: We screened 74 institutional repositories and two regional 
databases/archives. We found no information on RR of medical tests in 57 institutional repositories. 
The remaining 19 institutional archives provided 394 rapid evidence syntheses for further 
classification. After applying the selection criteria, we included 181 RRs of medical tests from 14 
institutions (Figure 1). 
Electronic databases: We identified 4,323 citations after removing duplicates. After screening by title 
and abstract, we selected 16 full-text articles for review, of which 10 met the criteria for inclusion. 
We did not identify any additional duplicates after combining information from all sources. In total, 
we included 191 unique RR in the review (Figure 1).   
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Figure 1. Study flow diagram: manual search of institutional repositories + electronic databases 
search 
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SYNTHESIS OF RESULTS 
Characteristics of included rapid reviews 
RR were developed by teams in 15 countries on four continents (three countries in America, 10 in 
Europe, one in Asia and one in Australia). In three countries (Argentina, Australia and Canada), more 
than two teams/institutions were involved in developing RR. Forty-seven RR (24.6%) were published 
in 2014. Review authors used different terms to describe the RR including “Rapid review”, “Rapid 
assessment”, “Rapid systematic review”, “Rapid report”, “Valutazione rapida” (Italian), “Rapid HTA 
report”, “Brief report”, “Revisión sistemática rápida” (Spanish), “Informe de respuesta rápida” 
(Spanish), “Scoping report” and “revisões rápidas de avaliação tecnológica em saúde” (Portuguese).  
The number of review authors involved in the development of RR ranged from 1 to 17. For RR 
published in institutional repositories, the median number of authors was seven (Interquartile range 
(IQR) 3 to 9 authors), similarly for those published in journals (median of authors, 7;  IQR, 3 to 8). 
Forty-three RR (22.5%) were developed by nine authors, while 30 (15.7%) were produced by seven 
authors. For RR published in a public repository, the estimated median production time was two 
months (IQR, 1 to 6.8 months), and for 41 RR (21.4%) was one month. For RR published in journals, 
the estimated median production time was eight months (IQR, 2.8 to 12.5 months). We were unable 
to estimate the production time for 96 RR. 
The composition of the review team was generally poorly reported. Twelve reviews (6.2%) reported a 
review coordinator or head of the team and 26 reviews (13.6%) reported the involvement of one or 
two information specialists. No review explicitly reported the participation of methodologists 
specialised in diagnostic evidence, statisticians, or patients. Nineteen RR (9%) reported that the 
intended audience was decision-makers belonging to their local healthcare system. The person 
commissioning the review was mentioned in 46 reviews (24%). However, no review explicitly 
reported involving the person commissioning the RR in its development. 
RR ranged in length from 2 to 120 pages (median length, 8 pages; IQR, 6 to 12 pages).  The main 
findings (excluding the cover page, references and appendices) were reported in 10 pages or less for 
122 reviews (63.8%). In addition, 48 RR (25.1%) reported an external peer-review process involving 
two or more experts, while 37 reviews (19.3%) explicitly reported asking for comments and 
suggestions from the public to incorporate in the final report. 
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Issues regarding the scope of the RR 
Only 81 RR (42%) provided explicit information about the population, index test, comparisons and 
outcomes in a structured format (i.e. a PICO  question) (Table 1). Most reports concerned 
information about patients with a specific target condition or disease. The target conditions most 
commonly reported were cancer and blood disorders (n=25), neurological disorders (n=21) and 
gastrointestinal diseases (n=20). 
Thirty-five reviews (18.3%) assessed the evidence for two or more index tests and 50 reviews (26.1%) 
for an unclear number of tests, described as a set of tests or tools (e.g. genetic panels, biomarkers, 
screening tools. The most commonly intended outcome was resource requirements (n=139; 72.7%), 
followed by effectiveness and safety (n=134; 70.1%), accuracy (n=124; 64.9%) and guideline 
recommendations (n=124; 64%). Sixty-eight reviews (35.6%) assessed more than three outcomes. 
Forty-nine RR (25.6%) appraised evidence on accuracy, effectiveness and safety, resource 
requirements and recommendations in the same report (Table 1). 
None of the included RR described the clinical pathway, in particular, the role of the test, reference 
standard, or prior tests. Fifity-six RR (29.3%) evaluated more than one application for the index tests; 
the most frequently reported were diagnosis (ruling in), followed by treatment monitoring, and 
screening or surveillance (Table 1).   
12 
 
Table 1. Characteristics of the scope of included rapid reviews 
Rapid reviews ‘scope 
 
Count (%) 
PICO question 81 (42.0) 
Target conditions  
Cancer & Blood 25 (13.0) 
Neurology 21 (10.9) 
Digestive disorders & gastrointestinal diseases 20 (10.4) 
Index test  
Single test 106 (55.5) 
Two tests or more 35 (18.3) 
Unclear (set of tests) 50 (26.2) 
Pre-planned outcomes  
Resource requirements 139 (72.7) 
Effectiveness/Safety 134 (70.1) 
Accuracy 124 (64.9) 
Recommendations 124 (64.9) 
Prediction/prognosis 31 (16.2) 
Values and preferences 9 (4.7) 
Number of outcomes to be assessed  
1 21 (11.0) 
2 38 (19.9) 
3 63 (33.0) 
More than 3 68 (35.6) 
Combination of outcomes  
Accuracy + Effectiveness/Safety + Resource requirements + Recommendations  49 (25.6) 
Accuracy + Resource requirements + Recommendations  17 (8.9) 
Effectiveness/Safety + Resource requirements + Recommendations 16 (8.3) 
Accuracy + Effectiveness/Safety + Resource requirements 10 (5.2) 
Effectiveness/Safety + Resource requirements 10 (5.2) 
Application of the test   
Diagnosis (ruling in) 120 (62.8) 
Treatment monitoring 33 (17.2) 
Screening or surveillance 28 (14.6) 
Grading and staging 23 (12.0) 
Risk assessment and classification 20 (10.4) 
Determining prognosis 18 (9.4) 
Treatment triage 13 (6.8) 
Ruling out disease/condition 1 (0.5) 
 
Note: Rapid reviews could have more than one pre-planned outcome or application.   
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Issues regarding parallelisation of tasks 
A considerable number of reviews did not provide information about the methods or researchers 
performing study selection or data extraction (Table 2). Of those reviews reporting information 
(n=68), 57 RR involved a single review author for citation screening and study selection. Only 10 
reviews reported the number of authors involved in data extraction (Table 2). 
In addition, 182 RR (95%) did not provide information about the process used to assess the 
methodological quality of included studies, although 77 reviews (40%) reported that they used a risk 
of bias checklist (Table 2). The quality appraisal tool most frequently reported was the Assessing the 
Methodological Quality of Systematic Reviews (AMSTAR-I) checklist (25, 26) (n=31), followed by the 
Appraisal of Guidelines Research and Evaluation (AGREE) checklist (27) (n=22) and the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS I/II) tool (28, 29) (n=19). Fifty-four RR also used 
other alternative quality assessment tools, including the Scottish Intercollegiate Guidelines Network 
(SIGN) checklists, the tools developed by the Critical Appraisal Skill Programme (CASP), and the 
Drummond’s checklist for assessing economic evaluations. 
Issues regarding rapid review shortcuts 
Seventy-two percent of the reviews included evidence from an existing SR to answer the review 
question. Other common sources of evidence were clinical practice guidelines and observational 
studies (e.g. case series, concordance studies or cohorts estimating risk) (Table 2). Thirty-four RR 
(17.8%) based their conclusions only on a previous evidence synthesis  (i.e. systematic reviews, 
clinical practice guidelines, economic studies or health technology assessment reports). 
Regarding the literature search, 76 reviews (39.7%) did not limit their searches. For the remaining RR, 
the most frequently applied limit was language, English-only (Table 2). For those reviews limiting by 
date (n=72), thirty-two (50%) limited the search to the last five years, while 22 (32%) limited it to the 
previous 10 years. Focused internet searches and checking of reference lists were additional 
resources frequently used by review authors (n=145; 75.9%). In addition, 133 RR (69.6%) used 
specialised search engines, such as the Centre for Reviews and Dissemination (CDR) database, the 
Cochrane Library or TripDatabase. 
Most RR (n=184; 96.3%) reported their findings in a narrative summary. Thirty-three reviews  (17.2%) 
explicitly mentioned the use of the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) approach to assess the certainty of the evidence. 
Issues regarding automated approaches 
No reviews reported the use of new technologies, such as machine learning or algorithms, for any of 
the steps involved in the development of the RR.  
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Table 2. Rapid review methods identified from data sources 
Rapid review method 
 
Count (%) 
Nature of the evidence included under findings  
Systematic reviews 139 (72.7) 
Clinical practice guidelines 118 (61.7) 
Observational studies (other than accuracy studies) 93 (48.6) 
Health Technology Assessment (HTA) reports 73 (38.2) 
Primary accuracy studies 68 (35.6) 
Randomised controlled trials 63 (32.9) 
Economic studies 49 (25.6) 
Qualitative studies 5 (2.6) 
Unclear 3 (1.5) 
Limits on the search  
Limit by language (English-only) 84 (43.9) 
Limit by date 72 (37.6) 
Limit by database (MEDLINE or PUBMED) 45 (23.5) 
Limit by using filters 27 (14.1) 
Update of an existing full systematic review 10 (5.2) 
Limit by outcome 5 (2.6) 
Limit by country 2 (1.0) 
No supplementary searches 10 (5.2) 
Selection of studies  
One reviewer 57 (29.8) 
Two reviewers, non-independent 2 (1.0) 
Two reviewers, independent 9 (4.7) 
Not reported 123 (64.3) 
Data extraction  
One reviewer 4 (2.0) 
Two reviewers, non-independent 2 (1.0) 
Two reviewers, independent 4 (2.0) 
Not reported/Not applicable 181 (94.7) 
Quality appraisal  
One reviewer 2 (1.0) 
Two reviewers, independent 3 (1.5) 
Not reported/NA 182 (95) 
Type of synthesis  
Narrative summary 184 (96.3) 
Meta-analysis 7 (3.6) 
GRADE approach 33 (17.2) 
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DISCUSSION 
To our knowledge, this is the first review that attempts to explore the characteristics and methods 
used in the production of RR of medical tests. We aimed to analyse whether well-known mechanisms 
to enhance the timeliness of RR (i.e. narrowing the scope, parallelisation of tasks, using review 
shortcuts and automating review steps) are being used in the development of RR of medical tests. 
We identified a considerable number of RR (n = 191), mostly published on institutional websites and 
developed by different teams globally. Previous reviews of RR identified a small proportion of 
reviews on diagnostic evidence, of which most included only accuracy outcomes (16, 24). 
 
We found that RR were typically developed by large teams (median 7 authors), produced relatively 
quickly (in less than 12 months), and concisely written (less than ten pages). These findings are 
consistent with the requirement of timeliness and feasibility of a rapid product (1, 5). However, due 
to poor reporting, we were unable to assess whether the team composition and its dynamics 
affected the development of these RR, specifically whether the project involved highly trained staff, a 
feature for developing RR that has been previously suggested (19). 
 
Beyond the description of the main characteristics of RR, our scoping review aimed to assess the use 
of mechanisms and strategies recommended for the development of RR (12). One of these strategies 
is limiting the extent of the review scope since a broader scope requires comprehensive and 
consistent review methods (i.e. a standard full systematic review) (21). However, we observed that 
RR addressed multiple elements in their scope, such as several index tests and different scenarios for 
test application. Moreover, we expected that authors of RR would consider only a limited number of 
outcomes (e.g. accuracy) (30), but instead, we found that they commonly included multiple 
outcomes. We also found that narrowing the scope of the review was infrequently used in the 
development of RR of medical tests. 
 
Using review shortcuts to abbreviate steps in the review process is another suggested method for 
streamlining development of RR, including the use of a single database, limiting electronic searches 
and omitting a search of the grey literature (16, 20, 23). However, we found that these review 
shortcuts were not generally applied in our set of RRs, including setting limits by date and language. 
(16, 20, 23). The narrative report of findings (i.e. the omission of a meta-analysis) was the only 
shortcut widely used, which is in agreement with previous assessments of rapid synthesis products 
(16, 20, 23). 
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Unfortunately, we found a lack of reporting of key methods, including study selection, data collection 
and quality appraisal. Thus, we were unable to assess whether mechanisms such as parallelisation of 
tasks or automated approaches were put into practice to speed preparation of these reviews. 
 
Despite shortfalls in reporting, we observed that RR of medical tests have characteristics similar to 
those in SR, such as searching multiple electronic databases, the inclusion of evidence from primary 
studies and the use of additional sources of evidence. Despite this, most RR included in our scoping 
review explicitly alerted the reader to the limitations of their review owing to the rapid approach 
used. 
 
Strengths of our review include the large number of RR of medical tests identifed and published in 
different countries and continents. We also used a strict definition of RR (i.e. True Rapid Review), 
which excludes other rapid products of knowledge synthesis, but is the most comparable synthesis to 
a SR (21). Our methodological approach has been previously used in other reviews assessing 
methods for the development of RR (16, 20). However, our review has several limitations. Selection 
of RR was limited to reports available in the public domain, and we cannot guarantee that we found 
all RR of medical tests. We also did not attempt to contact institutions without public repositories to 
collect additional information. Moreover, most of our findings came from five institutions that 
published 87% of the RR assessed in our study. It is also important to note that most RR were 
developed for Health Technology Assessment agencies. This might explain the broad scope 
previously described, which frequently included an extensive assessment of resource requirements. 
 
One conclusion of our study is the need for the standardisation of RR reporting in order to enhance 
transparency of methods employed for these rapid products. In 2016, Kelly et al. found that several 
key issues were poorly reported in a selection of RR, including protocol registration, the process of 
data collection, methods used for assessing the risk of bias, time for completion and the reporting of 
individual risk of bias assessment (24). Standardised guidelines for adequate reporting of RR would 
be helpful to determine the adequacy of the methods and the extent of the limitations on the review 
conclusions. We are aware that some efforts to develop the PRISMA for RR of interventions are 
currently underway (https://osf.io/t54fv/).  
Our scoping review also shows the need for additional research regarding which methods are 
appropriate for RR of medical tests. One example is the suitability of a narrow scope. If a mixture of 
evidence is needed to fulfill stakeholder needs and narrowing the scope is not an option, the 
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remaining mechanisms suggested to streamline the review process need to be carefully assessed. For 
a more in-depth investigation, our team will be conducting an international survey to investigate 
stakeholders’ and developers’ views on RRs of medical tests. In addition, we will explore potential 
challenges and discuss the implications for further development of RR of diagnostic tests with 
experts in the field (31). This information will be used in a research programme to identify the most 
appropriate methodological framework for conducting RR for diagnostic evidence, to be used by 
developers, stakeholders and decision-makers in the future.  
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Appendix 1. Search strategies in major databases 
Ovid MEDLINE(R) ALL <1946 to September 14, 2018> 
1     rapid review.mp. 
2     rapid review.ti,ab. 
3     (abbreviated adj review?).tw. 
4     (abbreviated adj synthes?s).tw. 
5     (accelerated adj2 review?).tw. 
6     (accelerated adj2 review?).tw. 
7     (brief adj synthes?s).tw. 
8     (expedited adj2 review?).tw. 
9     (expedited adj2 synthes?s).tw. 
10     (meta adj method$).tw. 
11     (meta adj evaluat$).tw. 
12     (rapid adj2 review?).tw. 
13     (rapid adj2 assess$).tw. 
14     "rapid health technology assess$".tw. 
15     (rapid adj HTA?).tw. 
16     (rapid adj approach$).tw. 
17     (rapid adj search$).tw. 
18     (realis$ adj approach$).tw. 
19     (realis$ adj evaluat$).tw. 
20     (realis$ adj synthes?s).tw. 
21     (speed$ adj2 review?).tw. 
22     (speed$ adj2 review?).tw. 
23     (streamline$ adj2 synthes?s).tw. 
24     (fast$ adj2 review?).tw. 
25     (fast$ adj2 synthes?s).tw. 
26     rapid report.ti,ab. 
27     rapid response.ti,ab. 
28     evidence brief.ti,ab. 
29     exp Animals/ not (exp Animals/ and Humans/) 
30     or/1-28 
31     30 not 29 
32     limit 31 to yr="2010 -Current"  
33     Diagnosis, Differential/  
34     Diagnostic Tests, Routine/ 
35     diagnos*.mp. 
36     diagnostic tool.ti,ab. 
37     (Sensitivity and Specificity).mp. 
38     diagnostic tool.ti,ab. 
39     (Sensitivity and Specificity).mp. 
40     sensitivit*.ab.  
41     specificit*.ab. 
42     accuracy*.ti,ab. 
43     false positive*.ti,ab.  
44     false negative*.ti,ab.  
45     accura*.ti,ab. 
46     (likelihood adj3 (ratio* or function*)).ab. 
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47     ((positive* or negative* or false or true) adj3 rate*).ti,ab. 
48     likelihood.ti,ab. 
49     reproducibility.ti,ab.  
50     or/33-49  
51     32 and 50  
52     case report.ti,ab. 
53     Case Reports/  
54     or/52-53  
55     51 not 54 
 
EMBASE ELSEVIER 
#1  'rapid review*/exp 
#2  abbreviated NEAR/2 review*  
#3  abbreviated NEAR/2 synthes* 
#4  accelerated NEAR/2 review*  
#5  brief NEAR/2 synthes* 
#6  expedited NEAR/2 review* 
#7  expedited NEAR/2 synthes* 
#8  meta NEAR/2 method* 
#9  meta NEAR/2 evaluat*  
#10  rapid NEAR/2 review*  
#11  rapid NEAR/2 asess*  
#12  'rapid health technology assess*  
#13  rapid NEAR/2 hta  
#14  rapid NEAR/2 approach*  
#15  rapid NEAR/2 search*  
#16  realis* NEAR/2 approach*  
#17  realis* NEAR/2 evaluat*  
#18  realis* NEAR/2 synthe*  
#19  speed NEAR/2 review*  
#20  streamline NEAR/2 'synthes*  
#21  fast NEAR/2 review*  
#22  fast NEAR/2 synthes*  
#23  'rapid report':ti,ab  
#24  'rapid response':ti,ab  
#25  'evidence brief':ti,ab  
#26  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25  
#27  'animals' NOT 'humans'  
#28  #26 NOT #27  
#29  #28 AND (2010:py OR 2011:py OR 2012:py OR 2013:py OR 2014:py OR 2015:py OR 2016:py 
OR 2017:py OR 2018:py OR 2019:py)  
#30  'differential diagnosis':ti,ab,kw  
#31  'diagnostic test' :ti,ab,kw 
#32  'diagnostic accuracy':ti,ab,kw  
#33  diagnos*:ti,ab,kw  
#34  'diagnosis':ti,ab,kw  
#35  sensitivity AND specificity:ti,ab  
#36  'sensitivity and specificity':ti,ab,kw  
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#37  'sensitivit*':ti,ab  
#38  'specificit*':ti,ab  
#39  'accuracy*':ti,ab  
#40  'false positive':ti,ab  
#41  'false negative':ti,ab  
#42  'accurac*':ti,ab  
#43  'likelihood ratio':ti,ab,kw  
#44  'likelihood function':ti,ab,kw  
#45  reproducibility:ti,ab  
#46  #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR 
#42 OR #43 OR #44 OR #45  
#47  #29 AND #46 
#48  #47 AND [embase]/lim NOT ([embase]/lim AND [medline]/lim) 
 
COCHRANE LIBRARY 
#1 rapid review  
#2 abbreviated adj review*  
#3 abbreviated adj synthes*  
#4 accelerated adj2 review*  
#5 brief adj synthes*  
#6 expedited adj2 review*  
#7 expedited adj2 synthes*  
#8 meta adj method*  
#9 meta adj evaluat*  
#10 rapid adj2 review  
#11 rapid adj2 assess*  
#12 rapid health technology assess*  
#13 rapid adj HTA*  
#14 rapid adj approach*  
#15 rapid adj search*  
#16 realis adj approach*  
#17 realis$ adj evaluat*  
#18 speed$ adj2 review*  
#19 streamline$ adj2 synthes*  
#20 fast$ adj2 review*  
#21 fast$ adj2 synthes?s  
#22 rapid report  
#23 rapid response  
#24 evidence brief  
#25 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or 
#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24  
#26 MeSH descriptor: [Diagnosis] explode all trees  
#27 diagnos*  
#28 MeSH descriptor: [Diagnostic Tests, Routine] explode all trees  
#29 diagnostic test* 
#30 diagnostic tool  
#31 MeSH descriptor: [Sensitivity and Specificity] explode all trees  
#32 Sensitivity and Specificity  
#33 sensitivit*  
#34 specificit*  
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#35 accuracy*  
#36 false positive*  
#37 false negative*  
#38 accura* 
#39 likelihood  
#40 reproducibility  
#41 #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR 
#38 OR #39 OR #40  
#42 #25 AND #41  
 
LILACS 
(tw:((tw:((tw:(revision rápida)))) OR (tw:(revision rapida  de la literatura)) OR (tw:(sintesis abreviada)) 
OR (tw:(sintesis corta)) OR (tw:(evaluacion* de tecnologia en salud)) OR (tw:(busqueda rapida)) OR 
(tw:(evaluacion rapida)) OR (tw:(sintesis rapida)))) AND (tw:((tw:(diagnos*)) OR (tw:(prueba 
diagnostica)) OR (tw:(herramienta diagnostica)) OR (tw:(sensibilidad)) OR (tw:(especificidad)) OR 
(tw:(falso* positivo)) OR (tw:(falso* negativo)) OR (tw:(reproduciblidad)) OR (tw:(likelihood)))) AND 
(instance:"regional") AND ( db:("LILACS" OR "IBECS" OR "BRISA" OR "CUMED" OR "BINACIS" OR 
"BDENF" OR "BBO" OR "PAHO") AND year_cluster:("2016" OR "2014" OR "2017" OR "2015" OR 
"2013" OR "2012" OR "2011" OR "2010")) 
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Appendix 2. Data extraction: List of variables and operational definitions 
Name of variable Definition 
Year Year of publication 
Country Country of publication 
Index test Name of index test(s) assessed in the report 
Number of index tests  Number of index tests assessed, including an unclear number 
Target condition Target condition(s) assessed in the report 
Applications of healthcare-
related tests/ Purpose 
See operational definitions below. Extracted from the background, rationale 
and objective of the review 
Number of purposes 
assessed 
Number of index test applications/purposes intended to be assessed in the 
review 
Data search If available, date of the information search reported by the authors of the 
review (including year and month) 
Publication date If available, date of the publication date reported by the authors of the 
review (including year and month) 
Time for development Timespan reported for review development. If no reported, estimated 
amount of time in months from the data search until the publication date 
Commissioner of the review If available, name or type of commissioner of the rapid review 
Intended audience If available, the intended audience of the report 
Involvement of 
commissioner 
If available, report if the commissioner has any role in the development of 
the rapid review 
Pre-planned outcomes Report the nature of the outcomes intended to be assessed in the rapid 
review. See operational definitions below. 
Number of predefined 
outcomes 
Number of predefined outcomes intended to be assessed in the rapid review.  
Team composition Report members of the team and roles, including review coordinator, review 
methodologist (specialist in diagnostic questions), information specialist, 
statistician, content expert and stakeholder. 
Type of studies included in 
findings 
Report the type of studies included under Results. See operational definitions 
below 
PICO question Report if a formal PICO question was provided (e.g. in a table). 
Issues about search of 
evidence 
Report strategies to expedite the search of information, including the 
following: update of a systematic review, limit by language, limit by outcome, 
limit by country, limit by date, limit by study design, limit by database, limit 
using filters, use of meta-searchers, limit trial registries, limit additional 
searches.  
Selection of studies Report how the study selection was conducted: one reviewer only, two 
reviewers/independently, two reviewers/checking, unclear selection. 
Collection of data Report how the data collection was conducted: one reviewer only, two 
reviewers/independently, two reviewers/checking, unclear collection. 
Quality appraisal Report how the methodological assessment of studies were conducted: one 
reviewer only, two reviewers/independently, two reviewers/checking, 
unclear assessment. 
Tools for quality assessment Report the tools/checklists applied in the assessment of the evidence (e.g., 
AMSTAR, QUADAS, AGREE, Cochrane RoB, other methods) 
Synthesis of evidence Report how the synthesis of information was performed (e.g., narrative 
synthesis, a meta-analysis of data) 
GRADE approach Report if the GRADE approach was used to evaluate the quality of the 
evidence. Check the findings and conclusions of the report. 
Peer-review process Inform if there was a peer-review process (internal/external) before the 
publication of the review 
Public consultation Inform if there was an open public consultation to receive comments and 
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suggestions before the publication of the final report 
Length of the report Number of pages of the rapid review (excluding cover, references and 
appendixes) 
 
Operational definitions 
Rapid products  
(Adapted from Hartling 2015 and Hartling 2017) 
Evidence inventories (EI) EI list what evidence is available and often other contextual information needed 
for making decisions but do no synthesis and do not attempt to present 
conclusions or recommendations. 
Rapid responses (RResp) RResp organise and evaluate the literature to present the end user with an 
answer based on the best available evidence but do not attempt to formally 
synthesise the evidence into a new conclusion 
True rapid review (TRR) TRR perform evidence synthesis (qualitative, quantitative, or both) to provide 
the end user with an answer about the findings from the evidence and possibly 
the strength of the evidence 
Automated approaches 
(AA) 
AA use databases of extracted study elements that use computer programming 
or algorithms to generate meta-analyses in response to user-defined queries. 
Applications of healthcare-related tests/ Purpose 
(Adapted from Mustafa 2017) 
Screening or surveillance Monitor the general population or a high-risk group for early detection of a 
disease/condition 
Risk assessment and 
classification 
Determine pre-test probability, the existence of specific risk groups and the 
need for close monitoring for a disease/condition 
Diagnosis/Ruling In Confirm the presence of a disease/condition 
Ruling out 
disease/condition 
Exclude presence of a disease/condition 
Treatment triage Determine appropriateness of starting treatment or type of treatment 
Treatment monitoring Follow-up for regression of a disease, possible recurrence, or appropriateness of 
continuing treatment or titrating it during and/or post-treatment 
Grading and staging Determine the severity of disease or phase of disease progression 
Determining prognosis A prediction of the probable course and subsequent outcome of a 
disease/condition 
 
 
Type of studies/Designs 
(Adapted from Porta 2008 and Cochrane Glossary (https://community.cochrane.org/glossary) 
Accuracy studies Studies focused on the ability of a diagnostic test to correctly classify the 
presence or absence of the target condition 
Observational studies A study that does not involve any intervention on the part of the investigator. 
We included all primary studies not focused on accuracy in this category, 
including risk cohorts, concordance studies, case series, among others 
Randomised controlled 
trials 
An epidemiological experiment in which subjects in a population are randomly 
allocated into groups to receive or not an experimental preventive or 
therapeutic procedure, manoeuvre, or intervention. 
Systematic reviews The application of strategies that limit bias in the assembly, critical appraisal, 
and synthesis of all relevant studies on a specific topic. 
Clinical practice 
guidelines 
Documents compiling formal statements about a defined task or function. For 
our study, we included in this category all reviews searching for 
recommendations. 
Economic studies The comparison of the relationship between costs and outcomes of alternative 
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healthcare interventions 
Qualitative studies Any type of research that employs non-numerical information to explore 
individual or group characteristics, producing findings not arrived at by statistical 
procedures or other quantitative means. 
HTA reports The formal evaluation of technologies used in health care, including medicine, 
and in public health. It explicitly involves not only efficacy, but also cost-
effectiveness, cost-utility, and all other aspects of technology that may be 
important for society. 
Pre-planned outcomes 
(Adapted from Porta 2008) 
Accuracy The ability of a diagnostic test to correctly classify the presence or absence of 
the target condition 
Effectiveness/Safety Effectiveness = A measure of the extent to which a specific intervention, 
procedure, regimen or service, when deployed in the field in the usual 
circumstances, does what it is intended to do in a specified population 
Safety = A measure of the negative results associated with an 
action/intervention, as well as the quantification of adverse effects that may 
result from exposure to specified health hazards or from the absence of 
beneficial influences 
Use of resources All costs, supplies and other assets incurred in producing a set quantity of 
service 
Values and preferences Concepts used to explain what we believe in, what we hold dear about the way 
we live, and how and why things matter. They are strong influences on the 
health of individuals and populations. 
Prediction/Prognosis The assessment of an attribute or exposure that is associated with an increased 
probability of a specified outcome. 
Recommendations Formal statements about a defined task or function 
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What is new?  
Key findings  
• Our scoping review identified 191 rapid reviews of medical tests from 15 countries 
published between 2013 and 2018. 
• Most rapid reviews were broad in scope and assessed multiple index tests, outcomes, and 
test applications. In general, well-known methodological tailoring strategies, such as 
setting limits for literature searching by date or language or searching a single database, 
were rarely used.  
• Information about parallelisation of tasks and the use of automated approaches was 
infrequently reported. 
 
 What this adds to what was known?  
• Rapid reviews of medical tests have many of the same characteristics and use similar 
methods as those of standard systematic reviews. However, we found that several critical 
items for rapid reviews were infrequently reported. 
 
What is the implication and what should change now? 
• Standards for reporting of rapid reviews are needed. Those standards would cover the 
essential items that should be included in every rapid review. 
• Further research should inform the most appropriate methods for performing rapid 
reviews of medical tests. 
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